Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
about
Role of a propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP-IV and DPP9One site mutation disrupts dimer formation in human DPP-IV proteinsDipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular DiseaseDPP4 in DiabetesPotential role of dipeptidyl peptidase IV in the pathophysiology of heart failureGLP-1-based strategies: a physiological analysis of differential mode of actionDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsProteolysis controls endogenous substance P levelsDeletion of PREPl causes growth impairment and hypotonia in miceCirculating CD26 is negatively associated with inflammation in human and experimental arthritis.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cellsGIP and GLP-1, the two incretin hormones: Similarities and differencesExpanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform.Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone RegenerationThe incretin system and cardiometabolic diseaseKinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.Analysis of the proteolysis of bioactive peptides using a peptidomics approach.Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides.Peptidomics of the prolyl peptidasesEmerging gliptins for type 2 diabetes.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunctionA novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis.Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cellsA peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.The role of incretins in glucose homeostasis and diabetes treatment.Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.Extracellular proteases as targets for drug development
P2860
Q24293344-90379D4E-D668-4889-B222-7779B93F8F97Q24305361-3EBD3B2F-1733-4FE1-B84B-F7B711323C72Q24813111-6A9C18D7-BFB6-4FF3-B6DD-574AB66E61F4Q26781269-23CB1BA1-C419-446F-99FE-909B923EA5E9Q26797335-9E284496-101E-4DD5-9708-61AB9EB165C3Q26829634-A4B8ABDB-3648-4DDA-96CF-294E76C35200Q26997149-8B87AF27-9DAB-40A0-9410-2B062ACA6C03Q27011819-68384F08-B566-47AE-876E-DAD8BA33AEE0Q28081569-FE2515D3-DACF-47BD-8BB5-FB523F852266Q28534739-5F8647EF-D721-482D-849A-56B196995B15Q28540232-16BAA34A-C41C-4246-8241-94BE5CB56169Q31144845-1D7DD09F-7C1B-43F8-9435-FDDB140AE1B1Q33237060-FCB85E2D-0FBD-4DD7-9F58-B2D06CB57797Q33428789-4B6D98C5-11B0-4968-AF5B-B80EB2F193F3Q33434017-94586347-2FCC-421B-952A-D26C9FE0B398Q33567322-34AB050F-82D8-4036-8550-B7D24A622B42Q33609502-88A242EB-9367-4ABA-93A6-C45C390CDDC1Q33742666-3DC279F7-D532-4734-AE46-C36BC3AB4CE9Q33750640-733A33D5-1006-4778-9DCE-D4886AB64794Q33765723-F2F2DC7A-1CD4-4221-8268-E7B8B8CEAC9EQ33776092-DDC64F4A-A75E-4721-964B-42C34262EE08Q34100605-BE4A7DC4-1062-4A26-9AD9-B483C3804EB9Q34222114-34C26D57-223C-4470-ABBD-F698D78985A6Q34268925-76E6C336-4FD6-4180-9339-A28A6B1FF0E1Q34293605-E603255E-8A7B-4F3F-AACD-D359FD33C262Q34347884-0320DC6C-F4DD-4174-8336-D6714E74CDADQ34452524-216503F2-F874-4A52-BB25-945F100A515AQ34468372-0B60A872-7440-4027-9AFF-F1C081E75B4DQ34478713-00573357-EEE2-4AC5-BFA9-5431F656E08EQ34533162-6F25B8C4-3517-4B64-9D23-24CFAFAEDB0BQ34569365-0892B6EA-CCE1-43B6-97B7-785267CE1055Q34589793-C642D511-45D0-4E51-832B-2EBF70036B17Q34626662-BC665B01-055E-4A21-99FF-4F0F937C3541Q34648201-D53C08F9-3931-4705-A813-16CDC6C79380Q34700818-371A1800-15F0-48EC-9EBB-79FC776C1085Q34795373-3D21BE8E-01BC-4A78-A95C-5874879F6068Q34888374-359EB3D2-9259-4EFD-BC3E-6DC9356CB764Q34901533-E09DE61D-D4F6-4F52-B0EA-9CC2762F9985Q35040181-4128E04B-5ABD-4339-BF5D-2F3CAAD96580Q35116202-4678191D-1480-4EFF-A250-6F917899BF73
P2860
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@ast
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@en
type
label
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@ast
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@en
prefLabel
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@ast
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@en
P2093
P2860
P356
P1476
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
@en
P2093
A M Bernard
D J Drucker
N Wagtmann
P F Nielsen
T Kobayashi
T Watanabe
P2860
P304
P356
10.1073/PNAS.120069197
P407
P577
2000-06-01T00:00:00Z